Scinovex
review Open AccessTop 1% cited

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

Journal of the American College of Cardiology · 2020 · Vol. 75(23) · pp. 2950–2973
Behnood BikdeliMahesh V. MadhavanDavid JiménezTaylor ChuichIsaac DreyfusElissa DrigginCaroline Der‐NigoghossianWalter AgenoMohammad MadjidYutao GuoLiang TangYu HuJay GiriMary CushmanI. QuéréEvangelos DimakakosC. Michael GibsonGiuseppe LippiEmmanuel J. FavaloroJawed FareedJoseph A. CapriniAlfonso TafurJohn BurtonDominic P. FranceseElizabeth WangAnna FalangaClaire McLintockBeverley J. HuntAlex C. SpyropoulosGeoffrey D. BarnesJohn W. EikelboomIdo WeinbergSam SchulmanMarc CarrierGregory PiazzaJoshua A. BeckmanPhilippe Gabríel StegGregg W. StoneStephan RosenkranzSamuel Z. GoldhaberSahil A. ParikhManuel MonréalHarlan M. KrumholzStavros KonstantinidesJeffrey I. WeitzGregory Y.H. Lip
Venous Thromboembolism Diagnosis and ManagementCOVID-19 Clinical Research StudiesAcute Myocardial Infarction ResearchMedicineAntithromboticIntensive care medicineDiseaseThrombosisPandemicVenous thrombosisCoronavirus disease 2019 (COVID-19)CoronavirusInternal medicine

MeSH terms

BetacoronavirusCOVID-19SARS-CoV-2AnticoagulantsFibrinolytic AgentsHumansPlatelet Aggregation InhibitorsPneumonia, ViralThromboembolismTreatment OutcomeCoronavirus InfectionsPandemics

Funding

  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Bayer HealthCare
  • European Society of Cardiology
  • Daiichi-Sankyo
  • LEO Pharma
  • National Institutes of Health
  • Irving Medical Center, Columbia University
  • National Heart, Lung, and Blood Institute
Citations
2,917
FWCI
345.31
field-weighted impact
References
161
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up · Scinovex